Back to search results

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Glioma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Northshore University Hospital, Manhasset, New York, United States

    Contact: Study coordinator (Ajith Vellat) · Avellat1@northwell.edu · 516-375-9053
    Contact: Principal Investigator (Michael Schulder, MD, FAANS)

  • UT Southwestern Medical Center, Dallas, Texas, United States

    Contact: Study coordinator (Omar Raslan) · Omar.Raslan@UTSouthwestern.edu · 214-648-6691
    Contact: Principal Investigator (Toral Patel, MD)

  • The Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States

    Contact: Study coordinator (Leticia Velten, RN) · velten@uthscsa.edu · 210-450-1921
    Contact: Principal Investigator (Andrew J Brenner, M.D., Ph.D.)
    John R Floyd, M.D. (Sub-investigator)
    William T Phillips, M.D. (Sub-investigator)
Study leads

  • Andrew J Brenner, PhD

    Principal Investigator

    The Cancer Therapy and Research Center at UTHSCSA

View source on ClinicalTrials.gov(opens in a new tab)